Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMAO), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative (Nasdaq: XOMAO) are linked to XOMA Royalty’s preferred stock and to a business model centered on biotechnology royalty aggregation. The XOMAO news feed captures company announcements that describe how XOMA Royalty acquires future economic rights to therapeutic candidates licensed to pharmaceutical and biotechnology partners, and how this activity relates to its preferred stock capital structure.
In its press releases, XOMA Royalty highlights transactions that shape its royalty and milestone portfolio. News items include strategic royalty sharing agreements, such as the amendment of a long-standing collaboration with Takeda involving mezagitamab and a basket of development-stage assets, as well as the acquisition of milestone and royalty interests tied to programs being developed by companies like Neurocrine Biosciences, Mirum Pharmaceuticals, Oak Hill Bio, and Recursion Pharmaceuticals. These disclosures explain how XOMA Royalty seeks to expand and diversify its economic exposure across multiple therapeutic areas and stages of development.
The news flow also covers corporate acquisitions that add new partnered pipelines and potential royalty streams. Recent announcements describe completed transactions to acquire HilleVax, LAVA Therapeutics, and Mural Oncology, where XOMA Royalty used cash consideration and contingent value rights in tender offers or schemes of arrangement. These updates detail the transaction structures, tender conditions, and subsequent delisting of the acquired companies’ shares from Nasdaq.
For holders and prospective investors in XOMAO, the news page provides insight into preferred stock dividends authorized by XOMA Royalty’s Board of Directors for the 8.375% Series B Cumulative Perpetual Preferred Stock depositary shares, along with timing and per-share dividend amounts. Financial results releases further describe royalty and milestone receipts from commercial assets such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, as well as business development activities that may influence future royalty flows.
By following XOMAO-related news, readers can track XOMA Royalty’s reported progress in building its portfolio of royalty and milestone rights, understand the terms of key transactions, and see how the company describes its role in providing non-dilutive, non-recourse funding to biotech counterparties. This context can be useful for those monitoring developments that may affect XOMA Royalty’s preferred stock and overall royalty aggregation strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.